Vitiligo is a chronic pigmentation disorder that is characterized by a reduction in the activity and number of melanocytes in the affected skin. The condition affects between 0.5% and 2% of the world’s population, with no obvious differences in incidence between males and females. Onset can occur in all age groups, but is most evident in the 10- to 30-year-old age group. Vitiligo is currently classified into segmental (SV) and nonsegmental (NSV), of which there are several variants: mucosal, focal, acrofacial, generalized, universal, and some rarer variants.

The clinic is characterized by the appearance of hypopigmented or achromic, non-desquamating, usually asymptomatic macules that can affect any part of the body, mostly symmetrically. the pathogenesis of vitiligo remains largely unknown, hence the difficulty in finding targeted and effective therapies, especially in the long term.

Several studies have recently shown that oxidative stress plays a primary role in the development of vitiligo. In this regard, melanocytes isolated from vitiligo patients have been shown to be more susceptible to oxidative stress-induced cell damage.

Do you want to read the whole article on JPD? Click here!